255 related articles for article (PubMed ID: 30642743)
1. Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells.
Dai X; Liu L; Liang Z; Guo K; Xu S; Wang H
Pathol Res Pract; 2019 Apr; 215(4):712-721. PubMed ID: 30642743
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression.
Zhang Y; Pitchiaya S; Cieślik M; Niknafs YS; Tien JC; Hosono Y; Iyer MK; Yazdani S; Subramaniam S; Shukla SK; Jiang X; Wang L; Liu TY; Uhl M; Gawronski AR; Qiao Y; Xiao L; Dhanasekaran SM; Juckette KM; Kunju LP; Cao X; Patel U; Batish M; Shukla GC; Paulsen MT; Ljungman M; Jiang H; Mehra R; Backofen R; Sahinalp CS; Freier SM; Watt AT; Guo S; Wei JT; Feng FY; Malik R; Chinnaiyan AM
Nat Genet; 2018 Jun; 50(6):814-824. PubMed ID: 29808028
[TBL] [Abstract][Full Text] [Related]
3. Silencing of MALAT1 inhibits migration and invasion by sponging miR‑1‑3p in prostate cancer cells.
Dai X; Liang Z; Liu L; Guo K; Xu S; Wang H
Mol Med Rep; 2019 Oct; 20(4):3499-3508. PubMed ID: 31485645
[TBL] [Abstract][Full Text] [Related]
4. Novel lncRNA
Lingadahalli S; Jadhao S; Sung YY; Chen M; Hu L; Chen X; Cheung E
Mol Cancer Res; 2018 Dec; 16(12):1865-1878. PubMed ID: 30115758
[TBL] [Abstract][Full Text] [Related]
5. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
6. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
[TBL] [Abstract][Full Text] [Related]
7. The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer.
Wang SH; Zhang WJ; Wu XC; Weng MZ; Zhang MD; Cai Q; Zhou D; Wang JD; Quan ZW
J Cell Mol Med; 2016 Dec; 20(12):2299-2308. PubMed ID: 27420766
[TBL] [Abstract][Full Text] [Related]
8. Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1.
Zhang P; Lu Y; Kong Z; Zhang Y; Fu F; Su X; Huang Y; Wan X; Li Y
Prostate; 2019 Jun; 79(9):994-1006. PubMed ID: 31012142
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
Jang YG; Go RE; Hwang KA; Choi KC
J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
12. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
Wang D; Wan X; Zhang Y; Kong Z; Lu Y; Sun X; Huang Y; Ji C; Li D; Luo J; Gu W; Wang C; Li Y; Xu Y
Prostate; 2019 Sep; 79(12):1362-1377. PubMed ID: 31269242
[TBL] [Abstract][Full Text] [Related]
13. A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer.
Shi Z; Chen J; Wumaner A; Li M; Liang C; Li M
Biochem Biophys Res Commun; 2021 Jan; 537():78-84. PubMed ID: 33387886
[TBL] [Abstract][Full Text] [Related]
14. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells.
Meng D; Yang S; Wan X; Zhang Y; Huang W; Zhao P; Li T; Wang L; Huang Y; Li T; Li Y
Int J Biochem Cell Biol; 2016 Apr; 73():30-40. PubMed ID: 26827675
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling.
Li Z; Teng J; Jia Z; Zhang G; Ai X
J Clin Lab Anal; 2021 Feb; 35(2):e23645. PubMed ID: 33219721
[TBL] [Abstract][Full Text] [Related]
16. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
17. A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression.
Fang Z; Xu C; Li Y; Cai X; Ren S; Liu H; Wang Y; Wang F; Chen R; Qu M; Wang Y; Zhu Y; Zhang W; Shi X; Yao J; Gao X; Hou J; Xu C; Sun Y
Cancer Lett; 2016 Apr; 374(1):62-74. PubMed ID: 26808578
[TBL] [Abstract][Full Text] [Related]
18. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells.
Liu XH; Kirschenbaum A; Yao S; Liu G; Aaronson SA; Levine AC
Cancer Res; 2007 Jun; 67(12):5747-53. PubMed ID: 17575141
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis.
Liu Y; Gao S; Du Q; Zhao Q
Int J Mol Med; 2019 Jan; 43(1):547-556. PubMed ID: 30387807
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503.
Qi H; Wen B; Wu Q; Cheng W; Lou J; Wei J; Huang J; Yao X; Weng G
Biomed Pharmacother; 2018 Jun; 102():326-332. PubMed ID: 29571017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
